Examining the role of thromboelastography in patients with COVID-19.
Document Type
Article
Publication Date
5-14-2025
Publication Title
Perfusion
Abstract
BackgroundCOVID-19 causes a severe respiratory distress syndrome. Systemic inflammation and hypercoagulability are common. These findings are often evaluated with non-specific markers, including CRP, D-dimer, and fibrinogen. We sought to evaluate thromboelastography (TEG) to better understand this complex coagulopathy.MethodsWe conducted a prospective observational study analyzing TEG results in hospitalized patients with COVID-19. TEG was performed on admission and at pre-set intervals. Based on the TEG findings, patients were deemed "hypercoagulable" or "not hypercoagulable." Clinical outcomes were recorded.Results88 patients were evaluated. 78/88 (89%) were hypercoagulable. 10% of the hypercoagulable group (8/78) died compared to none in the non-hypercoagulable group (0/10), with thrombotic events occurring in 9% (8/88), a higher requirement for O2 support in 19% (17/88), and prolonged length of stay exceeding 4 days for 74% (65/88). No statistical significant differences were observed between the groups for any of the four adverse events. Patients with complete fibrinolysis shutdown (Ly30 = 0) had more thrombotic events than those with Ly30 > 0 (30% vs 0%,
First Page
2676591251340967
Recommended Citation
Chen AL, Robbins M, Masters S, Boudiab E, Finn D, Peshel E, et al [Thomas G, Studzinski D, Truscott S, Watterworth C, Novotny N, Ivascu F, Iacco A] Examining the role of thromboelastography in patients with COVID-19. Perfusion. 2025 May 14:2676591251340967. doi: 10.1177/02676591251340967. Epub ahead of print. PMID: 40366108.
DOI
10.1177/02676591251340967
ISSN
1477-111X
PubMed ID
40366108
